164 related articles for article (PubMed ID: 17062694)
21. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models.
Tseng JC; Hurtado A; Yee H; Levin B; Boivin C; Benet M; Blank SV; Pellicer A; Meruelo D
Cancer Res; 2004 Sep; 64(18):6684-92. PubMed ID: 15374985
[TBL] [Abstract][Full Text] [Related]
22. Measles as a potential oncolytic virus.
Fielding AK
Rev Med Virol; 2005; 15(2):135-42. PubMed ID: 15546127
[TBL] [Abstract][Full Text] [Related]
23. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells.
Forster MD; Ormerod MG; Agarwal R; Kaye SB; Jackman AL
Cytometry A; 2007 Nov; 71(11):945-50. PubMed ID: 17712798
[TBL] [Abstract][Full Text] [Related]
25. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma.
Turk MJ; Waters DJ; Low PS
Cancer Lett; 2004 Sep; 213(2):165-72. PubMed ID: 15327831
[TBL] [Abstract][Full Text] [Related]
26. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
[TBL] [Abstract][Full Text] [Related]
27. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum.
Muñoz-Alía MÁ; Nace RA; Tischer A; Zhang L; Bah ES; Auton M; Russell SJ
PLoS Pathog; 2021 Feb; 17(2):e1009283. PubMed ID: 33534834
[TBL] [Abstract][Full Text] [Related]
28. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model.
Mader EK; Maeyama Y; Lin Y; Butler GW; Russell HM; Galanis E; Russell SJ; Dietz AB; Peng KW
Clin Cancer Res; 2009 Dec; 15(23):7246-55. PubMed ID: 19934299
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E; Atherton PJ; Maurer MJ; Knutson KL; Dowdy SC; Cliby WA; Haluska P; Long HJ; Oberg A; Aderca I; Block MS; Bakkum-Gamez J; Federspiel MJ; Russell SJ; Kalli KR; Keeney G; Peng KW; Hartmann LC
Cancer Res; 2015 Jan; 75(1):22-30. PubMed ID: 25398436
[TBL] [Abstract][Full Text] [Related]
30. Attenuated, oncolytic, but not wild-type measles virus infection has pleiotropic effects on human neutrophil function.
Zhang Y; Patel B; Dey A; Ghorani E; Rai L; Elham M; Castleton AZ; Fielding AK
J Immunol; 2012 Feb; 188(3):1002-10. PubMed ID: 22180616
[TBL] [Abstract][Full Text] [Related]
31. Persistent measles virus infection of mouse neural cells lacking known human entry receptors.
Abdullah H; Earle JA; Gardiner TA; Tangy F; Cosby SL
Neuropathol Appl Neurobiol; 2009 Oct; 35(5):473-86. PubMed ID: 19490430
[TBL] [Abstract][Full Text] [Related]
32. Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry.
Viejo-Borbolla A; Pizzato M; Blair ED; Schulz TF
Virus Res; 2005 Mar; 108(1-2):45-55. PubMed ID: 15681054
[TBL] [Abstract][Full Text] [Related]
33. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
[TBL] [Abstract][Full Text] [Related]
34. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A
Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584
[TBL] [Abstract][Full Text] [Related]
35. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
Fu X; Tao L; Zhang X
Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
[TBL] [Abstract][Full Text] [Related]
36. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
37. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
Brandler S; Tangy F
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
[TBL] [Abstract][Full Text] [Related]
38. Modeling of cancer virotherapy with recombinant measles viruses.
Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
[TBL] [Abstract][Full Text] [Related]
39. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination.
Baldo A; Galanis E; Tangy F; Herman P
Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840
[TBL] [Abstract][Full Text] [Related]
40. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein.
Conner J; Braidwood L; Brown SM
Gene Ther; 2008 Dec; 15(24):1579-92. PubMed ID: 18701918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
